Searched for
PFIZER ACQUIRING METSERA
US market today: Pfizer posts strong first-quarter, sees boost from recent legal winsPfizer reported higher-than-expected sales and profit on Tuesday and said a patent extension for its Vyndamax heart drug and a recent favor...- Ahead of its time, a GLP-1 drug almost made it out of IndiaFifteen years back, Zydus Lifesciences introduced ZYOG1, an oral GLP-1 agonist that sparked excitement for its implications in diabetes man...
- Weight-loss treatment: How has obesity medicine market become battleground for pharma giants like Pfizer, AstraZeneca, Eli Lilly?Obesity, weight-loss medicines: Novo has been scrambling to keep pace in the obesity drug race it started, losing ground to rival Eli Lilly...
- S&P 500, Nasdaq and Dow Jones see big rise as heavyweight tech stocks witness rebound: Galecto sees 250% gain, Sonder Holdings plunges; check top gainers and losers on November 10 and here’s how top indices performedWall Street saw a sharp rise on Monday, November 10, 2025. Major US indices like the S&P 500 and Nasdaq surged. This rally was powered by N...
- S&P 500, Dow Jones, and Nasdaq futures flat after big gains from AI companies boost Wall Street; here’s how key indices performedWall Street experienced a strong start to the week, with major indices like the S&P 500, Nasdaq, and Dow Jones closing sharply higher. This...
- Wall Street jumps, Nvidia and Palantir lead AI surgeIndian markets saw a strong rebound on Monday. Major technology and AI-related companies like Nvidia and Palantir experienced significant g...
- Pfizer to acquire obesity drug startup Metsera in $10 billion dealPfizer has agreed to acquire obesity drug developer Metsera for up to $86.25 a share, surpassing Novo Nordisk's final offer. This move mark...
- US stock market today: Nasdaq dropped 1.9%, S&P 500 lost 1.1%, Dow slipped 0.8% — What led to Wall Street turning red and why Tesla, Nvidia, Amazon, and Palantir sankUS stock market fell hard today as AI hype cracked. The Nasdaq plunged 1.9%, the S&P 500 slipped 1.1%, and the Dow lost 0.8%. Tesla slid 3....
- Pfizer, Novo Nordisk escalate bidding war for obesity drug developer MetseraA fierce bidding war is underway for Metsera, an obesity drug developer. Novo Nordisk has made a $10 billion offer, which Metsera considers...
- Pfizer sues Metsera, Novo Nordisk over rival obesity drug bidPfizer sued Metsera and Novo Nordisk, alleging Metsera breached its merger agreement by deeming Novo's $8.5 billion bid superior. Pfizer se...
- PFE stock rises 5.3% today: Pfizer seals Trump drug price deal with $70 billion U.S. investment and $7.3 billion Metsera weight-loss acquisitionPfizer Inc. (NYSE: PFE) experienced a significant uptick in its stock price following two major announcements on September 30, 2025. Presid...
- S&P 500, Nasdaq subdued after rally, Trump's visa crackdown weighsThe S&P 500 and Nasdaq experienced a subdued session on Monday, despite recent record highs, influenced by uncertainty surrounding potentia...
- Pfizer PFE stock, Metsera MTSR stock: Pfizer, Metsera share prices jump as deal worth over $7 billion gets thumbs upStock Market boom for both companies' shares came as Pfizer said on Monday it would acquire drug developer Metsera in a deal valued at up t...
- US stock market today: Dow, S&P 500, Nasdaq Pull Back from record highs as Gold hits fresh all-time peakUS stocks fell slightly as investors waited for Fed speeches and key inflation data. Gold hit a record high while Bitcoin and other cryptoc...
- Pfizer closes in on $7.3 billion takeover of anti-obesity drugmaker Metsera: ReportPfizer is close to acquiring Metsera, an anti-obesity drug developer. The deal could be worth $7.3 billion. Pfizer will pay $47.50 per shar...
Load More
